← Back to headlines
Barclays Raises Eli Lilly Price Target to $1,400 Amid Tirzepatide Momentum
Barclays has increased its price target for Eli Lilly to $1,400, highlighting the strong momentum of its drug Tirzepatide as a key factor.
5 May, 14:44 — 5 May, 14:44
Sources
Showing 1 of 1 sources
Related Stories
Volkswagen Approves Major Restructuring Plan Targeting 100,000 Jobs
25m ago
Trump Administration Seeks Supreme Court Approval for Mail Ballot Restrictions
57m ago
New US-Venezuela Oil Agreement Draws Sharp Criticism and Economic Skepticism
58m ago
Crusoe Secures $3 Billion Funding and Lands $13 Billion Cloud Deal
1h ago